# First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

> **NCT02661373** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 44 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** SJ733
- **DRUG:** Cobicistat

## Key facts

- **NCT ID:** NCT02661373
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-01
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-03-09
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-01-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661373, "First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT02661373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*